Regional
Australia
Hong Kong
Malaysia
Pakistan
Philippines
Taiwan
Singapore
Thailand
VietnamAngioDynamics Receives FDA Clearance for NanoKnife System for Prostate Cancer
Published on December 2024
AngioDynamics, Inc. has announced that it received FDA 510(k) clearance for its NanoKnife System for prostate tissue ablation. This approval follows the successful completion of the pivotal PRESERVE study, which demonstrated the system's safety effectiveness in treating intermediate-risk prostate cancer.
The NanoKnife System uses irreversible electroporation (IRE) technology to target and ablate prostate tissue while preserving critical functions, minimizing the life-altering complications often associated with traditional treatments. This milestone marks a significant step towards establishing the NanoKnife System as a standard, function-preserving treatment for prostate cancer.
In a related development, Picaso Hospital successfully performed Malaysia’s first NanoKnife procedures for prostate cancer on October 18, 2024, with support from Getz Healthcare Malaysia. For more information on using NanoKnife for your hospital, contact us.
For more details on the PRESERVE study, visit the AngioDynamics website.
Getz Healthcare is proud to be recognized as the leading distributor of medical equipment, devices and consumables, in Asia Pacific.
Our full-service distribution capabilities provide end-to-end representation of our business partners’ products, while delivering comprehensive service and solutions to our customers in all the countries we serve. Learn more
All product information listed on this site are for healthcare professionals only. Descriptions and specifications of the products listed on this site are provided by the manufacturer.